Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Baylor College of Medicine
Headquarters: Houston, TX, United States of America
Website: http://www.bcm.edu
Year Founded: 1969
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 19, 2025
Discovery & Translation
Science Spotlight: TGFβ drives long COVID inflammation via EBV
BioCentury’s roundup of translational innovations also includes boosting T cell antitumor activity via fructose, and a new Parkinson’s risk gene
BioCentury | May 14, 2024
Management Tracks
John Milad named CEO of CRISPR play ERS Genomics
Plus: Senhwa hires Jason Huang as CMO, and updates from Egle and The Jackson Laboratory
BioCentury | Dec 12, 2023
Distillery Therapeutics
Small-molecule TopBP1 inhibitor for breast and ovarian cancers
BioCentury | Sep 15, 2023
Discovery & Translation
Mini Cas protein iterations; plus Moderna’s Lassa virus vaccine and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 9, 2023
Discovery & Translation
Targeting IRE1 in KRASi-resistant tumors; plus AZ’s Cas9 variant and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 2, 2023
Discovery & Translation
Single-cell T cell atlas identifies new subsets; plus CoRegen’s cell therapy and more
BioCentury’s roundup of translational news
BioCentury | Jan 14, 2023
Discovery & Translation
Ubiquitin-regulation for tauopathies; plus Regeneron’s IL2RG mAb for T cell-driven disease and more
BioCentury’s round-up of translational news
BioCentury | Jan 10, 2023
Emerging Company Profile
Cajal: integrating anatomy and genetics to discover CNS targets
Seattle-based company is pairing genetics with the modern neuroanatomy tools to discover targets for Parkinson’s and Alzheimer’s
Items per page:
1 - 10 of 378